Bayer Bets Big On External Innovation With BridgeBio Acoramidis Pact

 
• By Kevin Grogan

The German major's internal R&D fortunes in the cardiovascular space have been mixed, with asundexian faltering in a recent atrial fibrillation trial, so getting hold of the European rights to BridgeBio's recently-filed ATTR-CM therapy is a timely boost.

Bayer cross night
• Source: Bayer

More from Cardiovascular

More from Therapy Areas